SCM
NKTR icon

Silverarc Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Silverarc Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-365
Closed -$20.8K – 90
2025
Q3 		$20.8K Buy
365
+19
+5% +$629 ﹤0.01% 81
2025
Q2 		$8.94K Buy
+346
New +$3.88K ﹤0.01% 64

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Silverarc Capital Management's NKTR Position: Q4 2025 in Review

Silverarc Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 365 shares — an estimated $20.8K sold.

Silverarc Capital Management first reported a position in NKTR in Q2 2025 and held it in 2 quarters. The position peaked at $20.8K in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

  • Silverarc Capital Management reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 365 Nektar Therapeutics shares in Q4 2025, an estimated $20.8K.
  • Silverarc Capital Management first reported a position in Nektar Therapeutics in Q2 2025 and held it in 2 quarters.
  • Silverarc Capital Management's Nektar Therapeutics position peaked at $20.8K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.